Iambic Therapeutics Files Large S-1/A Amendment (48 MB)
Iambic Therapeutics, Inc. (CIK 0001997038) filed an S-1/A amendment totaling 48 MB on October 8, 2026 — the largest IPO filing of the day — indicating intensive updates to clinical data, executive bios, and risk factor disclosures.
51CFO view：Large biotech S-1/A filings reflect heightened SEC scrutiny. CFOs must co-lead: non-GAAP R&D expense modeling tied to clinical milestones, ASC 730 R&D capitalization policy justification, medical affairs validation of risk language, and vetting executive bios for undisclosed sanctions or misconduct.
Iambic Therapeutics, Inc. (CIK 0001997038) filed an S-1/A amendment totaling 48 MB on October 8, 2026 — the largest IPO filing of the day — indicating intensive updates to clinical data, executive bios, and risk factor disclosures.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →